CDP 1050

Drug Profile

CDP 1050

Alternative Names: CDP-1050

Latest Information Update: 07 Jan 2011

Price : $50

At a glance

  • Originator Duke University; Johns Hopkins University
  • Developer Cordex Pharma
  • Class Heart failure therapies
  • Mechanism of Action Nitric oxide donors; Reactive oxygen species inhibitors; Ryanodine receptor calcium release channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Suspended Heart failure

Most Recent Events

  • 20 Feb 2009 Phase-I clinical trials in Heart failure in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top